BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 2012;7:e39131. [PMID: 22768296 DOI: 10.1371/journal.pone.0039131] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice. Sleep 2016;39:357-68. [PMID: 26446112 DOI: 10.5665/sleep.5444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Qi K, Wei C, Li Y, Sui N. Orexin receptors within the nucleus accumbens shell mediate the stress but not drug priming-induced reinstatement of morphine conditioned place preference. Front Behav Neurosci 2013;7:144. [PMID: 24133421 DOI: 10.3389/fnbeh.2013.00144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
3 Martin EJ, Hernandez ME, Hayward LF. Blockade of orexin receptors attenuates the cardiovascular response to air-jet stress in spontaneously hypertensive rats. Auton Neurosci 2016;201:8-16. [PMID: 27591948 DOI: 10.1016/j.autneu.2016.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
4 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Heiss JE, Yamanaka A, Kilduff TS. Parallel Arousal Pathways in the Lateral Hypothalamus. eNeuro 2018;5:ENEURO. [PMID: 30225361 DOI: 10.1523/ENEURO.0228-18.2018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
7 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
8 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Vazquez-DeRose J, Schwartz MD, Nguyen AT, Warrier DR, Gulati S, Mathew TK, Neylan TC, Kilduff TS. Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain. Brain Struct Funct 2016;221:923-40. [PMID: 25431268 DOI: 10.1007/s00429-014-0946-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
10 Christopher JA, Aves SJ, Brown J, Errey JC, Klair SS, Langmead CJ, Mace OJ, Mould R, Patel JC, Tehan BG, Zhukov A, Marshall FH, Congreve M. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. Med Chem Commun 2015;6:947-55. [DOI: 10.1039/c5md00027k] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
11 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
12 Morairty SR, Wilk AJ, Lincoln WU, Neylan TC, Kilduff TS. The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Front Neurosci 2014;8:3. [PMID: 24550767 DOI: 10.3389/fnins.2014.00003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
13 Equihua AC, De La Herrán-Arita AK, Drucker-Colin R. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 2013;4:163. [PMID: 24416019 DOI: 10.3389/fphar.2013.00163] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
14 Perin M, Longordo F, Massonnet C, Welker E, Lüthi A. Diurnal inhibition of NMDA-EPSCs at rat hippocampal mossy fibre synapses through orexin-2 receptors. J Physiol 2014;592:4277-95. [PMID: 25085886 DOI: 10.1113/jphysiol.2014.272757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
15 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
16 Sanchez-Alavez M, Benedict J, Wills DN, Ehlers CL. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal. Sleep 2019;42:zsz020. [PMID: 30715515 DOI: 10.1093/sleep/zsz020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
17 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
18 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
19 Thomas AM, Schwartz MD, Saxe MD, Kilduff TS. Sleep/Wake Physiology and Quantitative Electroencephalogram Analysis of the Neuroligin-3 Knockout Rat Model of Autism Spectrum Disorder. Sleep 2017;40. [PMID: 28958035 DOI: 10.1093/sleep/zsx138] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
20 Parks GS, Warrier DR, Dittrich L, Schwartz MD, Palmerston JB, Neylan TC, Morairty SR, Kilduff TS. The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. Neuropsychopharmacology 2016;41:1144-55. [PMID: 26289145 DOI: 10.1038/npp.2015.256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Thomas AM, Schwartz MD, Saxe MD, Kilduff TS. Cntnap2 Knockout Rats and Mice Exhibit Epileptiform Activity and Abnormal Sleep-Wake Physiology. Sleep 2017;40. [PMID: 28364455 DOI: 10.1093/sleep/zsw026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
22 Prince CD, Rau AR, Yorgason JT, España RA. Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1. ACS Chem Neurosci 2015;6:138-46. [PMID: 25496218 DOI: 10.1021/cn500246j] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
23 Rihel J, Schier AF. Sites of action of sleep and wake drugs: insights from model organisms. Curr Opin Neurobiol 2013;23:831-40. [PMID: 23706898 DOI: 10.1016/j.conb.2013.04.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
24 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, Jacobson LH, Laue G, Ofner S, Chaudhari V, Badiger S, Pandit C, Wagner J, Hoyer D. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013;56:7590-607. [PMID: 23964859 DOI: 10.1021/jm4007627] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
26 Hasegawa E, Yanagisawa M, Sakurai T, Mieda M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest 2014;124:604-16. [PMID: 24382351 DOI: 10.1172/JCI71017] [Cited by in Crossref: 96] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
27 Viviani D, Haegler P, Jenck F, Steiner MA. Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat. Psychopharmacology (Berl) 2015;232:1383-93. [PMID: 25319964 DOI: 10.1007/s00213-014-3769-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
28 Iyer SH, Aggarwal A, Warren TJ, Hallgren J, Abel PW, Simeone TA, Simeone KA. Progressive cardiorespiratory dysfunction in Kv1.1 knockout mice may provide temporal biomarkers of pending sudden unexpected death in epilepsy (SUDEP): The contribution of orexin. Epilepsia 2020;61:572-88. [PMID: 32030748 DOI: 10.1111/epi.16434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Bruni O, Angriman M, Calisti F, Comandini A, Esposito G, Cortese S, Ferri R. Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. J Child Psychol Psychiatr 2018;59:489-508. [DOI: 10.1111/jcpp.12812] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
30 Nevárez N, de Lecea L. Hypocretin and the Regulation of Sleep-Wake Transitions. Handbook of Sleep Research. Elsevier; 2019. pp. 89-99. [DOI: 10.1016/b978-0-12-813743-7.00006-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
32 Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, Pippel DJ, Rizzolio M, Shelton JE, Shah CR, Shireman BT, Young LK, Yun S. Novel Octahydropyrrolo[3,4- c ]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate. J Med Chem 2015;58:5620-36. [DOI: 10.1021/acs.jmedchem.5b00742] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
33 Steiner MA, Sciarretta C, Pasquali A, Jenck F. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol 2013;4:165. [PMID: 24416020 DOI: 10.3389/fphar.2013.00165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
34 Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 2013;8:898-903. [PMID: 23589487 DOI: 10.1002/cmdc.201300003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
35 Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
36 Hoyer D, Dürst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci 2013;7:235. [PMID: 24368893 DOI: 10.3389/fnins.2013.00235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
37 Christopher JA. Small-molecule antagonists of the orexin receptors. Pharm Pat Anal 2014;3:625-38. [PMID: 25489915 DOI: 10.4155/ppa.14.46] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
38 Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci 2014;8:28. [PMID: 24592208 DOI: 10.3389/fnins.2014.00028] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
39 Carrive P. Orexin, Stress and Central Cardiovascular Control. A Link with Hypertension? Neurosci Biobehav Rev 2017;74:376-92. [PMID: 27477446 DOI: 10.1016/j.neubiorev.2016.06.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
40 Tarasiuk A, Levi A, Berdugo-Boura N, Yahalom A, Segev Y. Role of orexin in respiratory and sleep homeostasis during upper airway obstruction in rats. Sleep 2014;37:987-98. [PMID: 24790278 DOI: 10.5665/sleep.3676] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
41 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
42 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
43 Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. J Med Chem 2015;58:4648-64. [PMID: 25953512 DOI: 10.1021/acs.jmedchem.5b00217] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
44 Burfeind KG, Yadav V, Marks DL. Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation. Curr Neurol Neurosci Rep 2016;16:98. [PMID: 27662896 DOI: 10.1007/s11910-016-0700-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
45 Kuduk SD, Skudlarek JW, Di Marco CN, Bruno JG, Pausch MA, O’brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorganic & Medicinal Chemistry Letters 2014;24:1784-9. [DOI: 10.1016/j.bmcl.2014.02.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
46 Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci 2014;8:8. [PMID: 24550770 DOI: 10.3389/fnins.2014.00008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
47 Dittrich L, Morairty SR, Warrier DR, Kilduff TS. Homeostatic sleep pressure is the primary factor for activation of cortical nNOS/NK1 neurons. Neuropsychopharmacology 2015;40:632-9. [PMID: 25139062 DOI: 10.1038/npp.2014.212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
48 Mezeiova E, Janockova J, Konecny J, Kobrlova T, Benkova M, Dolezal R, Prchal L, Karasova-Zdarova J, Soukup O, Korabecny J. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia. Bioorg Chem 2020;103:104179. [PMID: 32891860 DOI: 10.1016/j.bioorg.2020.104179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Szabadi E. Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders. Drug Discovery Today 2014;19:701-8. [DOI: 10.1016/j.drudis.2014.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
50 Sakurai T. Orexin deficiency and narcolepsy. Curr Opin Neurobiol 2013;23:760-6. [PMID: 23663890 DOI: 10.1016/j.conb.2013.04.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
51 Carrive P. Orexin, orexin receptor antagonists and central cardiovascular control. Front Neurosci 2013;7:257. [PMID: 24415993 DOI: 10.3389/fnins.2013.00257] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
52 Greenwald MK, Moses TEH, Roehrs TA. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities. Transl Res 2021;234:58-73. [PMID: 33711513 DOI: 10.1016/j.trsl.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Beig MI, Horiuchi J, Dampney RA, Carrive P. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus. Clin Exp Pharmacol Physiol 2015;42:1059-67. [DOI: 10.1111/1440-1681.12461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
54 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
55 Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep 2020;43:zsz302. [PMID: 31830270 DOI: 10.1093/sleep/zsz302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
56 Berro LF, Moreira-Junior EDC, Rowlett JK. The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys. Drug Alcohol Depend 2021;227:108930. [PMID: 34358767 DOI: 10.1016/j.drugalcdep.2021.108930] [Reference Citation Analysis]
57 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
58 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
59 Kuduk SD, Winrow CJ, Coleman PJ. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. Elsevier; 2013. pp. 73-87. [DOI: 10.1016/b978-0-12-417150-3.00006-5] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
60 Walker LC, Ch’ng SS, Lawrence AJ. Role of Lateral Hypothalamic Orexin (Hypocretin) Neurons in Alcohol Use and Abuse: Recent Advances. Curr Pharmacol Rep 2016;2:241-52. [DOI: 10.1007/s40495-016-0069-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
61 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
62 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
63 Mieda M, Tsujino N, Sakurai T. Differential roles of orexin receptors in the regulation of sleep/wakefulness. Front Endocrinol (Lausanne) 2013;4:57. [PMID: 23730297 DOI: 10.3389/fendo.2013.00057] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
64 Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;27:83-90. [PMID: 23359095 DOI: 10.1007/s40263-012-0036-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
65 Lalovic B, Majid O, Aluri J, Landry I, Moline M, Hussein Z. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. J Clin Pharmacol 2020;60:1642-54. [PMID: 32666570 DOI: 10.1002/jcph.1683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Martin T, Dauvilliers Y, Koumar OC, Bouet V, Freret T, Besnard S, Dauphin F, Bessot N. Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise. Sci Rep 2019;9:18432. [PMID: 31804545 DOI: 10.1038/s41598-019-54826-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Brodnik ZD, Bernstein DL, Prince CD, España RA. Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behav Brain Res 2015;291:377-84. [PMID: 26049058 DOI: 10.1016/j.bbr.2015.05.051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
68 Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice. Sleep 2016;39:357-68. [PMID: 26446112 DOI: 10.5665/sleep.5444] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
69 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
70 Ruan W, Yuan X, Eltzschig HK. Circadian rhythm as a therapeutic target. Nat Rev Drug Discov 2021;20:287-307. [PMID: 33589815 DOI: 10.1038/s41573-020-00109-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
71 Morairty SR, Dittrich L, Pasumarthi RK, Valladao D, Heiss JE, Gerashchenko D, Kilduff TS. A role for cortical nNOS/NK1 neurons in coupling homeostatic sleep drive to EEG slow wave activity. Proc Natl Acad Sci U S A 2013;110:20272-7. [PMID: 24191004 DOI: 10.1073/pnas.1314762110] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
72 Schwartz MD, Kilduff TS. The Neurobiology of Sleep and Wakefulness. Psychiatr Clin North Am 2015;38:615-44. [PMID: 26600100 DOI: 10.1016/j.psc.2015.07.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 11.9] [Reference Citation Analysis]
73 Mieda M. The roles of orexins in sleep/wake regulation. Neuroscience Research 2017;118:56-65. [DOI: 10.1016/j.neures.2017.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
74 Carrive P, Kuwaki T. Orexin and Central Modulation of Cardiovascular and Respiratory Function. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 157-96. [DOI: 10.1007/7854_2016_46] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
75 Futamura A, Suzuki R, Tamura Y, Kawamoto H, Ohmichi M, Hino N, Tokumaru Y, Kirinuki S, Hiyoshi T, Aoki T, Kambe D, Nozawa D. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia. Bioorganic & Medicinal Chemistry 2020;28:115489. [DOI: 10.1016/j.bmc.2020.115489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Yao L, Ramirez AD, Roecker AJ, Fox SV, Uslaner JM, Smith SM, Hodgson R, Coleman PJ, Renger JJ, Winrow CJ, Gotter AL. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. J Neurochem 2017;142:204-14. [PMID: 28444767 DOI: 10.1111/jnc.14055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
77 Mercer SP, Roecker AJ, Garson S, Reiss DR, Meacham Harrell C, Murphy KL, Bruno JG, Bednar RA, Lemaire W, Cui D, Cabalu TD, Tang C, Prueksaritanont T, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs). Bioorg Med Chem Lett 2013;23:6620-4. [PMID: 24215892 DOI: 10.1016/j.bmcl.2013.10.045] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
78 Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Doré AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J Med Chem 2020;63:1528-43. [PMID: 31860301 DOI: 10.1021/acs.jmedchem.9b01787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
79 Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther 2017;362:287-95. [PMID: 28559480 DOI: 10.1124/jpet.117.241422] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
80 Schwartz MD, Nguyen AT, Warrier DR, Palmerston JB, Thomas AM, Morairty SR, Neylan TC, Kilduff TS. Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate Hypocretin/Orexin Antagonist-Mediated REM Sleep. eNeuro. 2016;3:pii: ENEURO.0018-16.2016. [PMID: 27022631 DOI: 10.1523/eneuro.0018-16.2016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
81 Zarrabian S, Riahi E, Karimi S, Razavi Y, Haghparast A. The potential role of the orexin reward system in future treatments for opioid drug abuse. Brain Research 2020;1731:146028. [DOI: 10.1016/j.brainres.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
82 Li SB, Nevárez N, Giardino WJ, de Lecea L. Optical probing of orexin/hypocretin receptor antagonists. Sleep 2018;41. [PMID: 30060151 DOI: 10.1093/sleep/zsy141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
83 Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, Kotz CM, Zhang Y. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. J Med Chem 2021;64:8806-25. [PMID: 34101446 DOI: 10.1021/acs.jmedchem.1c00841] [Reference Citation Analysis]
84 Boss C, Roch C. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opin Ther Pat 2016;26:409-15. [PMID: 26593218 DOI: 10.1517/13543776.2016.1124087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Kim SJ, Pilowsky PM, Farnham MM. Intrathecal Intermittent Orexin-A Causes Sympathetic Long-Term Facilitation and Sensitizes the Peripheral Chemoreceptor Response to Hypoxia in Rats. J Pharmacol Exp Ther 2016;358:492-501. [PMID: 27384072 DOI: 10.1124/jpet.116.234443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
86 Dalal J, Roh JH, Maloney SE, Akuffo A, Shah S, Yuan H, Wamsley B, Jones WB, de Guzman Strong C, Gray PA, Holtzman DM, Heintz N, Dougherty JD. Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. Genes Dev 2013;27:565-78. [PMID: 23431030 DOI: 10.1101/gad.207654.112] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
87 Amodeo LR, Wills DN, Sanchez-Alavez M, Ehlers CL. Effects of an Orexin-2 Receptor Antagonist on Sleep and Event-Related Oscillations in Female Rats Exposed to Chronic Intermittent Ethanol During Adolescence. Alcohol Clin Exp Res 2020;44:1378-88. [PMID: 32424852 DOI: 10.1111/acer.14361] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
89 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
90 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
91 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
92 Bruni O, Angriman M, Melegari MG, Ferri R. Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders. Expert Opinion on Pharmacotherapy 2019;20:2257-71. [DOI: 10.1080/14656566.2019.1674283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]